2. Academic Validation
  3. Discovery of A-967079 as an Enterovirus D68 Antiviral by Targeting the Viral 2C Protein

Discovery of A-967079 as an Enterovirus D68 Antiviral by Targeting the Viral 2C Protein

  • ACS Infect Dis. 2024 Dec 13;10(12):4327-4336. doi: 10.1021/acsinfecdis.4c00678.
Haozhou Tan 1,  Brian Pollard 1,  Kan Li 1,  Jun Wang 1
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.
PMID: 39578369 DOI: 10.1021/acsinfecdis.4c00678
Abstract

Enterovirus D68 (EV-D68) has had several outbreaks worldwide, yet no FDA-approved Antiviral is available for treating this viral Infection. EV-D68 Infection typically leads to respiratory illnesses and, in severe cases, can cause neurological complications and even death, particularly in children. This study identified a small molecule, A-967079, as an EV-D68 Antiviral through phenotypical screening. A-967079 has shown potent and broad-spectrum Antiviral activity with a high selectivity index against multiple strains of EV-D68. Pharmacological characterization of the mechanism of action involving time-of-addition, Resistance Selection, and differential scanning fluorimetry assays suggests that viral 2C protein is the drug target. Overall, A-967079 represents a promising candidate for further development as an EV-D68 Antiviral.

Keywords

A-967079; EV-D68; acute flaccid myelitis; antiviral; enterovirus D68.

Figures
Products